PureTech Scientific Completes Acquisition of Cymer Chemical’s Dayton, Tennessee Facility
PureTech Scientific Expands U.S. Manufacturing Footprint with Acquisition of Cymer Chemical’s Dayton, Tennessee Facility
PureTech Scientific, a global leader in high-purity glycolic acid innovation and manufacturing, announced today the acquisition of Cymer Chemical’s Dayton, Tennessee operation, a specialty tolling manufacturer known for its expertise in chemical processing development, blending and formulation, sample analysis, organic synthesis, and pilot-scale programs. The acquisition represents a major milestone in PureTech’s continued expansion and its strategic mission to enhance innovation, production capacity, and customer reach across the Life Sciences and Specialty Chemical markets.
Founded and backed by Iron Path Capital, a private equity firm focused on lower-middle-market investments in specialty industrial and healthcare sectors, PureTech continues to execute on its long-term growth strategy by integrating high-value, operationally sound assets with strong development potential.
This acquisition marks a significant step forward in our long-term growth strategy,” said Jake Fitzgerald, CEO of PureTech Scientific. “By integrating this facility and its talented workforce into our organization, we’re gaining advanced technical capabilities and deepening our expertise in the Life Sciences segment. We’re excited to welcome our new team members and look forward to building new value and innovation together.”
Strengthening Manufacturing Capabilities and Expanding Product Offerings
The Dayton, Tennessee facility—now operating as PureTech Scientific – Dayton, TN—will play a critical role in expanding PureTech’s manufacturing capabilities. The site produces glycolic acid across several grades, enabling PureTech to further purify and refine its own products for ultra-high-purity applications. Beyond serving the company’s internal needs, the facility will also provide chemical processing and manufacturing services to external partners, offering specialty production capabilities, pilot testing, and tolling services for a wide range of customers.
This acquisition allows PureTech to vertically integrate more of its production processes, ensuring greater control over product quality, supply chain resilience, and responsiveness to customer demands. It also strengthens the company’s ability to produce customized chemical formulations, supporting clients in industries such as personal care, pharmaceuticals, electronics, industrial cleaning, and biodegradable materials.
A Strategic Move Supported by Iron Path Capital
The transaction aligns closely with Iron Path Capital’s investment philosophy—targeting companies and assets with strong fundamentals, clear market differentiation, and potential for accelerated growth.
This carve-out deal of an established business with strong fundamentals, untapped potential, and a clear path to accelerated growth represents exactly the type of opportunity we look for,” said Scott Mraz, Co-founder of Iron Path Capital. “We’re proud to support PureTech Scientific as it enters this next phase of development, investing in innovation, operational excellence, and long-term value creation.”
Iron Path Capital’s partnership with PureTech reflects a shared vision for sustained growth through strategic acquisitions, operational efficiency, and continuous innovation. The Dayton facility will serve as an anchor for future expansion, both in production capability and customer service.
A Legacy of Innovation and Sustainable Growth
PureTech Scientific was established in 2023 following a carve-out acquisition from The Chemours Company, one of the global leaders in chemical innovation. Since its founding, the company has focused on leveraging its technical expertise, experienced workforce, and strong customer relationships to drive innovation and product development across multiple markets.
PureTech’s growth strategy centers on long-term investments in research and development, customer-centric product design, and sustainable manufacturing. By combining its proprietary technologies with the additional capabilities gained through this acquisition, the company aims to create new formulations and applications tailored to evolving market needs—particularly within Life Sciences, Specialty Chemicals, and clean technology sectors.
Industry-Leading Portfolio of Glycolic Acid Solutions
PureTech Scientific’s environmentally responsible and biodegradable portfolio includes several market-leading glycolic acid products designed for both industrial and consumer applications:
- Glypure® – A premium, high-purity glycolic acid widely used in personal care products such as anti-aging and wrinkle reduction serums, exfoliating peels, moisturizers, and acne treatments.
- Glypure® GL – A next-generation glycolic acid derivative that provides the rejuvenating benefits of alpha hydroxy acids (AHA) with significantly lower skin irritation and enhanced efficacy.
- Glypure® PGA – Featuring exceptionally low impurity levels, this grade supports the synthesis of high molecular weight polyglycolic acid, a key ingredient in the biodegradable plastics and medical device industries.
- Glyclean® – A technical-grade glycolic acid essential to industrial cleaning, electronics manufacturing, and semiconductor processing, known for its effective and sustainable performance.
- Glyclean® D – A recently developed formulation designed for the cleaning and disinfecting markets, offering superior environmental compatibility and cleaning power.
Each of these solutions highlights PureTech’s commitment to sustainability, purity, and performance—core values that drive its innovation strategy and customer relationships.
A Sustainable Future Rooted in Science
PureTech Scientific is the sole manufacturer of ultra-high-purity alpha hydroxy acids in the Americas, serving global markets with more than 85 years of operational experience. Headquartered in Belle, West Virginia, the company is dedicated to minimizing its environmental impact while maintaining world-class standards in quality and product safety.
Its advanced manufacturing processes and R&D initiatives are designed not only to meet evolving industry regulations but also to anticipate future sustainability requirements. By integrating Cymer Chemical’s operations, PureTech is positioning itself to further enhance energy efficiency, waste reduction, and process optimization across its production network.
The addition of the Dayton facility strengthens our ability to innovate responsibly,” added Fitzgerald. “We are committed to advancing green chemistry and sustainable production while continuing to deliver the exceptional quality our customers rely on.
About PureTech Scientific
PureTech Scientific LLC is a global leader in the organic synthesis of ultra-high-purity alpha hydroxy acids for the Life Sciences and Specialty Chemical industries. As the only manufacturer of glycolic acid in the Americas, PureTech provides innovative, sustainable solutions for applications ranging from personal care and pharmaceuticals to electronics and industrial cleaning. Headquartered in Belle, West Virginia, the company is driven by its mission to advance human and environmental health through science-based innovation and responsible manufacturing.
For more information, visit puretechscientific.com.
About Iron Path Capital
Iron Path Capital is an operationally focused private equity firm that invests in lower-middle-market companies within the healthcare and specialty industrial sectors. With offices in Nashville, Tennessee, and Charlottesville, Virginia, Iron Path partners with management teams to accelerate growth through strategic capital deployment, operational expertise, and long-term business development support. The firm targets businesses with stable cash flows, scalable models, and multiple pathways for growth—both organic and through consolidation.
Learn more at ironpathcapital.com.
